Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Maja Tarailo-Graovac, PhD
PhD in Medical Genetics, Medicine, UBC, Vancouver BC, CanadaPost-doctorate in Genomics Molecular Biology and Biochemistry, Science, SFU, Burnaby BC, Canada
Research Associate in Applied (Clinical) Genomics Medical Genetics, Medicine, UBC, Vancouver BC, Canada
Areas of Research
Genomics of Rare Genetic Disease, Medical Genomics, Genetic Modifiers, Model Organisms, Whole Genome Sequencing/Bioinformatics
My research program uses multidisciplinary approach (human and model organism genomics; ‘wet’ and ‘dry’ lab approaches) to understand the rare disease genomics. Rare diseases are typically monogenic and individually very rare but collectively affect at least 1 in 50 individuals. The recent advances (less than a decade old) in high throughput sequencing technology (HTPS) have revolutionized diagnosis and discovery of novel rare disease genes by enabling the entire genome (whole genome sequencing, WGS) or a protein-coding portion (whole exome sequencing, WES) to be read in a single test. My group has three main research interests:
My research program uses multidisciplinary approach (human and model organism genomics; ‘wet’ and ‘dry’ lab approaches) to understand the rare disease genomics. Rare diseases are typically monogenic and individually very rare but collectively affect at least 1 in 50 individuals. The recent advances (less than a decade old) in high throughput sequencing technology (HTPS) have revolutionized diagnosis and discovery of novel rare disease genes by enabling the entire genome (whole genome sequencing, WGS) or a protein-coding portion (whole exome sequencing, WES) to be read in a single test. My group has three main research interests:
Diagnostic potential of HTPS
Unlike exome sequencing, genome sequencing has the potential to detect all classes of genetic variation of an individual in one experiment. One goal of my research program is to further improve the detection and interpretation of an entire spectrum of genetic variation in a genome using HTPS. Together with novel gene-disease associations, this can improve diagnostic efficiency.
Unlike exome sequencing, genome sequencing has the potential to detect all classes of genetic variation of an individual in one experiment. One goal of my research program is to further improve the detection and interpretation of an entire spectrum of genetic variation in a genome using HTPS. Together with novel gene-disease associations, this can improve diagnostic efficiency.
Phenotypic variability in rare diseases
Incomplete penetrance and variable expressivity make it difficult to determine accurate prognosis of disease progression and expected outcome. Although the extent of both remains largely unknown for rare disease, recent large-scale sequencing projects (thousands of ‘healthy’ people sequenced) and data aggregation consortia allow us to assess the phenotypic variability in rare disease.
Incomplete penetrance and variable expressivity make it difficult to determine accurate prognosis of disease progression and expected outcome. Although the extent of both remains largely unknown for rare disease, recent large-scale sequencing projects (thousands of ‘healthy’ people sequenced) and data aggregation consortia allow us to assess the phenotypic variability in rare disease.
Genetic Modifiers
The ultimate goal of my research program is to understand why two individuals with the same rare disease-causing variant may have different clinical presentation of the disease (severe-milde-none)? In other words, we are asking whether other variants in a genome exist that may alleviate or exacerbate the severity of the disease-causing variant. To reach this goal, we combine an elegance of <i>Caenorhabditis elegans’</i> genetics/genomics with human genomics (e.g. discordant siblings), as well as the above noted advances in variant detection/interpretation and data aggregation. <i><b>Genetic modifiers are super cool</b></i> as they teach us about biological networks of human disease genes and may provide a clue for better therapeutics design.
The ultimate goal of my research program is to understand why two individuals with the same rare disease-causing variant may have different clinical presentation of the disease (severe-milde-none)? In other words, we are asking whether other variants in a genome exist that may alleviate or exacerbate the severity of the disease-causing variant. To reach this goal, we combine an elegance of <i>Caenorhabditis elegans’</i> genetics/genomics with human genomics (e.g. discordant siblings), as well as the above noted advances in variant detection/interpretation and data aggregation. <i><b>Genetic modifiers are super cool</b></i> as they teach us about biological networks of human disease genes and may provide a clue for better therapeutics design.
Supervising degrees
Biochemistry and Molecular Biology - Doctoral: Accepting Inquiries
Biochemistry and Molecular Biology - Masters: Accepting Inquiries
Working with this supervisor
We are looking for highly motivated graduate students and postdoctoral fellows. The ideal candidates will either have strong computational or genetic background, where knowledge of both will be considered an asset.
Contact this supervisor
Complete the following form if you are interested in working with this supervisor for your Graduate Program. All fields are required, unless indicated otherwise.